Priscilla Selig
Family · Daytona Beach, FLNPI 1447860374
Payments from drug & device makers
Across 210 payments — averaging $17.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Novo Nordisk$494
- Pfizer$384
- AstraZeneca$374
- GSK$302
- Lilly USA, LLC$97
- plus $803 from 15 others
What the payments were for
- Food & beverage$3,570100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 81 | $1,116 |
| Novo Nordisk | 24 | $494 |
| Pfizer | 19 | $384 |
| AstraZeneca | 18 | $374 |
| GSK | 20 | $302 |
| Lilly USA, LLC | 5 | $97 |
| Exact Sciences | 5 | $91 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 5 | $83 |
| Bayer | 4 | $75 |
| Novartis | 4 | $74 |
| Corium, LLC | 3 | $71 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $71 |
| Alk-abello, Inc | 3 | $65 |
| Boehringer Ingelheim | 3 | $58 |
| Vanda Pharmaceuticals Inc. | 3 | $54 |
| Amgen | 3 | $51 |
| Sanofi | 1 | $27 |
| Johnson & Johnson | 1 | $25 |
| Dynavax Technologies Corporation | 1 | $25 |
| Biohaven Pharmaceuticals, Inc. | 1 | $16 |
| Axsome Therapeutics, Inc. | 1 | $16 |
How this compares
$3,570 in reported general payments places this provider in the 90th percentile of 14,618 family providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 51 | $50,345 |
| OzempicSemaglutide | 37 | $42,142 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 25 | $24,781 |
| FarxigaDapagliflozin Propanediol | 18 | $17,905 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 19 | $15,940 |
| Spiriva RespimatTiotropium Bromide | 17 | $13,852 |
| SymbicortBudesonide/Formoterol Fumarate | 25 | $9,404 |
| CreonLipase/Protease/Amylase | 17 | $5,898 |
| Breo ElliptaFluticasone/Vilanterol | 12 | $4,435 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 19 | $2,507 |
| Atorvastatin Calcium | 308 | $2,375 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 111 | $2,315 |
| Wixela InhubFluticasone Propion/Salmeterol | 22 | $1,888 |
| Estradiol | 44 | $1,461 |
| Gabapentin | 107 | $1,417 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $384 | $50,34551 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $374 | $43,24862 claims |
| Novo NordiskOzempic | $494 | $42,14237 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $302 | $29,21637 claims |
| Boehringer IngelheimSpiriva Respimat | $58 | $13,85217 claims |
| AbbVieCreon | $1,116 | $5,89817 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 14,618 family providers in Florida.
Other family in Daytona Beach
- Tina GaskinDaytona Beach$39K
- John HuffakerVenice$8M
- Stephanie MompointMiami$4.5M
- Miguel TrujilloMiami Gardens$4.4M
- Itsel Cardenas RamonMiami$1M
- Lewis HarringtonTampa$954K
- Adam StrosbergFort Lauderdale$859K
- Danielle PharesFt Lauderdale$713K
- David RodriguezHialeah$658K
- Donna OrtizOrlando$417K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.